LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Core Insights - LIXTE Biotechnology Holdings, Inc. has initiated a clinical trial combining its compound LB-100 with GSK's immunotherapy Dostarlimab for treating ovarian clear cell cancer, with the first patient dosed at the Lurie Cancer Center [1][2][3] - The trial aims to assess the effectiveness of LB-100 in enhancing immunotherapy outcomes for a disease with high unmet medical needs [3] - The addition of Lurie Cancer Center as a trial site is expected to expand the patient population and accelerate the clinical trial process, which began in January 2024 at The University of Texas MD Anderson Cancer Center [3] Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing new cancer therapies, particularly through its first-in-class PP2A inhibitor, LB-100 [4] - LB-100 has shown potential for improving patient outcomes when used alongside various chemotherapies or immunotherapies, supported by extensive preclinical data [4] - The company operates in a unique field of cancer biology known as activation lethality, with a comprehensive patent portfolio protecting its innovations [4]